cometadata/datacite-titles-descriptions-related-identifiers huggingface dataset:
DOI: 10.6084/m9.figshare.19159200
title: Additional file 13 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 13: Table S1. Table listing abbreviations used for all the 22 cell types from LM22 and 10 cell types from LM10 utilized for deconvolution.
DOI: 10.6084/m9.figshare.19159203.v1
title: Additional file 14 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 14: Table S2. Table listing cluster memberships for each sample derived from cluster of cluster analysis of immune based clusters.
DOI: 10.6084/m9.figshare.19159206.v1
title: Additional file 15 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 15: Table S3. Table listing inhouse samples with scRNA Seq, with cell type annotation and scRNA derived signature matrix.
DOI: 10.6084/m9.figshare.19159200.v1
title: Additional file 13 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 13: Table S1. Table listing abbreviations used for all the 22 cell types from LM22 and 10 cell types from LM10 utilized for deconvolution.
DOI: 10.6084/m9.figshare.19159203
title: Additional file 14 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 14: Table S2. Table listing cluster memberships for each sample derived from cluster of cluster analysis of immune based clusters.
DOI: 10.6084/m9.figshare.19159206
title: Additional file 15 of Immune cell gene expression signatures in diffuse glioma are associated with IDH mutation status, patient outcome and malignant cell state, and highlight the importance of specific cell subsets in glioma biology

description: Additional file 15: Table S3. Table listing inhouse samples with scRNA Seq, with cell type annotation and scRNA derived signature matrix.
DOI: 10.6084/m9.figshare.19159254
title: Additional file 1 of Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019

description: Additional file 1: Table S1. Plasmodium falciparum K13 nucleotide sequences from 2019-study.
DOI: 10.6084/m9.figshare.19159254.v1
title: Additional file 1 of Biennial surveillance of Plasmodium falciparum anti-malarial drug resistance markers in Democratic Republic of Congo, 2017 and 2019

description: Additional file 1: Table S1. Plasmodium falciparum K13 nucleotide sequences from 2019-study.
DOI: 10.6084/m9.figshare.19159288
title: Additional file 1 of Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: qualitative findings from Japan

description: Additional file 1: Table S1. The descriptions of recovery process categories by collating existing CHIME frameworka.
DOI: 10.6084/m9.figshare.19159288.v1
title: Additional file 1 of Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: qualitative findings from Japan

description: Additional file 1: Table S1. The descriptions of recovery process categories by collating existing CHIME frameworka.
DOI: 10.6084/m9.figshare.19159291
title: Additional file 2 of Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: qualitative findings from Japan

description: Additional file 2: Table S2. The concept of personal recovery for mental health service users in Japan and selected narratives from the interviews.
DOI: 10.6084/m9.figshare.19159291.v1
title: Additional file 2 of Culture-dependent and universal constructs and promoting factors for the process of personal recovery in users of mental health services: qualitative findings from Japan

description: Additional file 2: Table S2. The concept of personal recovery for mental health service users in Japan and selected narratives from the interviews.
DOI: 10.6084/m9.figshare.18517638
title: Additional file 2 of Microbial colonization and persistence in deep fractured shales is guided by metabolic exchanges and viral predation

description: Additional file 1: Table S1. Chemical composition of frack fluids used in STACK 14, 16, and 17. Table S2. Metabolite and conductivity data. Table S3. Metagenomic sequencing and assembly, and 16S sequencing. Table S4. Linear discriminant analysis effect size (LEfSe) analysis of metabolite profiles for STACK-14 and STACK-16 & 17 frack fluids. Table S5. Relative abundance and genome statistics for the 24 dominant and persisting STACK MAGs. Table S6. Alpha diversity statistics for STACK and Appalachian Basin wells. Table S7. Osmoprotection genes and categorization for Figure S5. Figure S1. Statistically discernable microbial communities of inputs. Figure S2. Possible organic carbon sources inferred via genes encoding carbohydrate active enzymes (CAZymes). Figure S3. Genomic signatures for five of the 24 dominant and persisting microorganisms in input samples. Figure S4. Viral taxonomy and subsets of vMAGs unique to each well. Figure S5. Potential osmoprotection strategies in the dominant STACK MAGs.
DOI: 10.6084/m9.figshare.18517638.v1
title: Additional file 2 of Microbial colonization and persistence in deep fractured shales is guided by metabolic exchanges and viral predation

description: Additional file 1: Table S1. Chemical composition of frack fluids used in STACK 14, 16, and 17. Table S2. Metabolite and conductivity data. Table S3. Metagenomic sequencing and assembly, and 16S sequencing. Table S4. Linear discriminant analysis effect size (LEfSe) analysis of metabolite profiles for STACK-14 and STACK-16 & 17 frack fluids. Table S5. Relative abundance and genome statistics for the 24 dominant and persisting STACK MAGs. Table S6. Alpha diversity statistics for STACK and Appalachian Basin wells. Table S7. Osmoprotection genes and categorization for Figure S5. Figure S1. Statistically discernable microbial communities of inputs. Figure S2. Possible organic carbon sources inferred via genes encoding carbohydrate active enzymes (CAZymes). Figure S3. Genomic signatures for five of the 24 dominant and persisting microorganisms in input samples. Figure S4. Viral taxonomy and subsets of vMAGs unique to each well. Figure S5. Potential osmoprotection strategies in the dominant STACK MAGs.
DOI: 10.6084/m9.figshare.19159443.v1
title: Additional file 6 of DIX domain containing 1 (DIXDC1) modulates VEGFR2 level in vasculatures to regulate embryonic and postnatal retina angiogenesis

description: Additional file 6. Individual Value
DOI: 10.6084/m9.figshare.19159432.v1
title: Additional file 1 of Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

description: Additional file 1: Online data supplement and supplementary videos.
DOI: 10.6084/m9.figshare.19159471.v1
title: Additional file 1 of Effects of fire history on animal communities: a systematic review

description: Additional file 1: Appendix S1. Paper database.
DOI: 10.6084/m9.figshare.19159480.v1
title: Additional file 4 of Effects of fire history on animal communities: a systematic review

description: Additional file 4: Appendix S4. R Script to estimate effect sizes, perform linear models, and draw figures.
DOI: 10.6084/m9.figshare.19159405.v1
title: Additional file 9 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 9: Table S5. Summary of differentially-regulated proteins found in the label-free based quantitative proteomic analysis of control and pre-eclamptic serum exosomes from sample collections C1–C3. Only statistically significant differences (q
DOI: 10.6084/m9.figshare.19159402.v1
title: Additional file 8 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 8: Table S4. Functional analysis of proteins identified in sample collections C1–C3. Information related to tissue specificity, developmental stage and involvement in disease was obtained from public repositories.
DOI: 10.6084/m9.figshare.19159399.v1
title: Additional file 7 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 7: Table S3c. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159398.v1
title: Additional file 2 of Robust meta-analysis for large-scale genomic experiments based on an empirical approach

description: Additional file 2. R code for the proposed method (BACON adjusted Weighted Z).
DOI: 10.6084/m9.figshare.19159393.v1
title: Additional file 6 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 6: Table S3b. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159392.v1
title: Additional file 5 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 5: Table S5. Estimates of COVID-19 hospital acquired infections grouped by country.
DOI: 10.6084/m9.figshare.19159390.v1
title: Additional file 5 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 5: Table S3a. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159389.v1
title: Additional file 4 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 4: Table S4. Estimates of COVID-19 hospital acquired infections grouped by patient age-groups.
DOI: 10.6084/m9.figshare.19159387.v1
title: Additional file 4 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 4: Table S2. MRM transition list used in the targeted proteomic analysis of the 66 proteins detected with at least two proteotypic peptides (except for syndecan from C2 sample collection).
DOI: 10.6084/m9.figshare.19159386.v1
title: Additional file 3 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 3: Table S3. Summary of studies included in the scoping review.
DOI: 10.6084/m9.figshare.19159384.v1
title: Additional file 3 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 3: Table S1. Summary of serum control and pre-eclampsia samples used in this study.
DOI: 10.6084/m9.figshare.19159372.v1
title: Additional file 13 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 13: Table S9. Label-free-based quantitative proteomic analysis results obtained at in vitro stimulation assays of BeWo cells using exosomes isolated from serum.
DOI: 10.6084/m9.figshare.19159369.v1
title: Additional file 12 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 12: Table S8. Statistical analysis of the MRM results corresponding to the 66 proteins detected with at least two proteotypic peptides (except for syndecan from C2 sample collection).
DOI: 10.6084/m9.figshare.19159366.v1
title: Additional file 11 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 11: Table S7. Functional analysis of the differentially-regulated proteins described for sample collections C1–C3.
DOI: 10.6084/m9.figshare.19159363.v1
title: Additional file 10 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 10: Table S6. Comparison of proteomic quantitative results of proteins shared between sample collections C1–C3.
DOI: 10.6084/m9.figshare.19159321.v1
title: Additional file 1 of Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept

description: Additional file 1: Figure S1. a–d Representative SD-OCT of Study Patient. a Patient presented with a new onset choroidal neovascular membrane with visual acuity of 20/80. b Patient was managed with four intravitreal bevacizumab injections and was felt to be a sub-optimal responder even though vision improved to 20/40. c After switching to intravitreal aflibercept, the patients vision improved to 20/30 at the three-month time period with decreasing central macular thickness. d Visual acuity is maintained at 20/30 after three years of consistent intravitreal aflibercept therapy with injections given approximately every 6–8 weeks with no central macular fluid
DOI: 10.6084/m9.figshare.19159480
title: Additional file 4 of Effects of fire history on animal communities: a systematic review

description: Additional file 4: Appendix S4. R Script to estimate effect sizes, perform linear models, and draw figures.
DOI: 10.6084/m9.figshare.19159471
title: Additional file 1 of Effects of fire history on animal communities: a systematic review

description: Additional file 1: Appendix S1. Paper database.
DOI: 10.6084/m9.figshare.19159443
title: Additional file 6 of DIX domain containing 1 (DIXDC1) modulates VEGFR2 level in vasculatures to regulate embryonic and postnatal retina angiogenesis

description: Additional file 6. Individual Value
DOI: 10.6084/m9.figshare.19159432
title: Additional file 1 of Effect of indacaterol/glycopyrronium on ventilation and perfusion in COPD: a randomized trial

description: Additional file 1: Online data supplement and supplementary videos.
DOI: 10.6084/m9.figshare.19159405
title: Additional file 9 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 9: Table S5. Summary of differentially-regulated proteins found in the label-free based quantitative proteomic analysis of control and pre-eclamptic serum exosomes from sample collections C1–C3. Only statistically significant differences (q
DOI: 10.6084/m9.figshare.19159402
title: Additional file 8 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 8: Table S4. Functional analysis of proteins identified in sample collections C1–C3. Information related to tissue specificity, developmental stage and involvement in disease was obtained from public repositories.
DOI: 10.6084/m9.figshare.19159399
title: Additional file 7 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 7: Table S3c. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159398
title: Additional file 2 of Robust meta-analysis for large-scale genomic experiments based on an empirical approach

description: Additional file 2. R code for the proposed method (BACON adjusted Weighted Z).
DOI: 10.6084/m9.figshare.19159393
title: Additional file 6 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 6: Table S3b. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159392
title: Additional file 5 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 5: Table S5. Estimates of COVID-19 hospital acquired infections grouped by country.
DOI: 10.6084/m9.figshare.19159390
title: Additional file 5 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 5: Table S3a. Total number of peptides (FDR
DOI: 10.6084/m9.figshare.19159389
title: Additional file 4 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 4: Table S4. Estimates of COVID-19 hospital acquired infections grouped by patient age-groups.
DOI: 10.6084/m9.figshare.19159387
title: Additional file 4 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 4: Table S2. MRM transition list used in the targeted proteomic analysis of the 66 proteins detected with at least two proteotypic peptides (except for syndecan from C2 sample collection).
DOI: 10.6084/m9.figshare.19159386
title: Additional file 3 of Hospital acquired COVID-19 infections amongst patients before the rollout of COVID-19 vaccinations, a scoping review

description: Additional file 3: Table S3. Summary of studies included in the scoping review.
DOI: 10.6084/m9.figshare.19159384
title: Additional file 3 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 3: Table S1. Summary of serum control and pre-eclampsia samples used in this study.
DOI: 10.6084/m9.figshare.19159372
title: Additional file 13 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 13: Table S9. Label-free-based quantitative proteomic analysis results obtained at in vitro stimulation assays of BeWo cells using exosomes isolated from serum.
DOI: 10.6084/m9.figshare.19159369
title: Additional file 12 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 12: Table S8. Statistical analysis of the MRM results corresponding to the 66 proteins detected with at least two proteotypic peptides (except for syndecan from C2 sample collection).
DOI: 10.6084/m9.figshare.19159366
title: Additional file 11 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 11: Table S7. Functional analysis of the differentially-regulated proteins described for sample collections C1–C3.
DOI: 10.6084/m9.figshare.19159363
title: Additional file 10 of Quantitative proteomic analysis of serum-purified exosomes identifies putative pre-eclampsia-associated biomarkers

description: Additional file 10: Table S6. Comparison of proteomic quantitative results of proteins shared between sample collections C1–C3.
DOI: 10.6084/m9.figshare.19159321
title: Additional file 1 of Long term results of patients with neovascular age-related macular degeneration switched from other anti-VEGF agents to intravitreal Aflibercept

description: Additional file 1: Figure S1. a–d Representative SD-OCT of Study Patient. a Patient presented with a new onset choroidal neovascular membrane with visual acuity of 20/80. b Patient was managed with four intravitreal bevacizumab injections and was felt to be a sub-optimal responder even though vision improved to 20/40. c After switching to intravitreal aflibercept, the patients vision improved to 20/30 at the three-month time period with decreasing central macular thickness. d Visual acuity is maintained at 20/30 after three years of consistent intravitreal aflibercept therapy with injections given approximately every 6–8 weeks with no central macular fluid
DOI: 10.26180/13393676
title: Dataset for Nogueira Alves et al: Ecdysone coordinates plastic growth with robust pattern in the developing wing

description: These files contain all datasets and scripts used in the manuscript.
DOI: 10.26180/13393676.v3
title: Dataset for Nogueira Alves et al: Ecdysone coordinates plastic growth with robust pattern in the developing wing

description: These files contain all datasets and scripts used in the manuscript.
DOI: 10.26180/13393676.v2
title: Dataset for Nogueira Alves et al: Ecdysone coordinates plastic growth with robust pattern in the developing wing

description: These files contain all datasets and scripts used in the manuscript.
DOI: 10.5517/ccdc.csd.cc28zvvz
title: CCDC 2115032: Experimental Crystal Structure Determination

description: Related Article: Yun Dai, Wei Meng, Xiangqing Feng, Haifeng Du|2022|Chem.Commun.|58|1558|doi:10.1039/D1CC06964K
DOI: 10.5517/ccdc.csd.cc29095t
title: CCDC 2115445: Experimental Crystal Structure Determination

description: Related Article: Ruth Weller, Markus Balmer, Carsten von Hänisch, C. Gunnar Werncke|2022|Dalton Trans.|51|1765|doi:10.1039/D1DT03805B
DOI: 10.5517/ccdc.csd.cc290qhk
title: CCDC 2115858: Experimental Crystal Structure Determination

description: Related Article: Lingyun Wang, Zeliang Chen, Xueguang Ran, Hao Tang, Derong Cao|2022|Inorg.Chem.Commun.|137|109246|doi:10.1016/j.inoche.2022.109246
DOI: 10.5517/ccdc.csd.cc290wz6
title: CCDC 2116028: Experimental Crystal Structure Determination

description: Related Article: Dushanthi S. Dissanayake, Gregory T. McCandless, and Michael C. Biewer|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x08
title: CCDC 2116029: Experimental Crystal Structure Determination

description: Related Article: Jia Du, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x19
title: CCDC 2116030: Experimental Crystal Structure Determination

description: Related Article: Jia Du, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x2b
title: CCDC 2116031: Experimental Crystal Structure Determination

description: Related Article: Chandima Bulumulla, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x4d
title: CCDC 2116033: Experimental Crystal Structure Determination

description: Related Article: Chandima Bulumulla, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x5f
title: CCDC 2116034: Experimental Crystal Structure Determination

description: Related Article: Chandima Bulumulla, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc290x6g
title: CCDC 2116035: Experimental Crystal Structure Determination

description: Related Article: Yixin Ren, Gregory T. McCandless, and Mihaela C. Stefan|2021|CSD Communication|||
DOI: 10.5517/ccdc.csd.cc2910v7
title: CCDC 2116148: Experimental Crystal Structure Determination

description: Related Article: Peng Yang, Qiang Wang, Bing-Hui Cui, Xiao-Dong Zhang, Hang Liu, Yue-Yuan Zhang, Jia-Liang Liu, Wen-Yu Huang, Ren-Xiao Liang, Yi-Xia Jia|2022|J.Am.Chem.Soc.|144|1087|doi:10.1021/jacs.1c11092
DOI: 10.5517/ccdc.csd.cc2910x9
title: CCDC 2116150: Experimental Crystal Structure Determination

description: Related Article: Peng Yang, Qiang Wang, Bing-Hui Cui, Xiao-Dong Zhang, Hang Liu, Yue-Yuan Zhang, Jia-Liang Liu, Wen-Yu Huang, Ren-Xiao Liang, Yi-Xia Jia|2022|J.Am.Chem.Soc.|144|1087|doi:10.1021/jacs.1c11092